vs
Side-by-side financial comparison of Bandwidth Inc. (BAND) and Bio-Techne (TECH). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($295.9M vs $208.8M, roughly 1.4× Bandwidth Inc.). Bio-Techne runs the higher net margin — 12.8% vs 1.9%, a 10.9% gap on every dollar of revenue. On growth, Bandwidth Inc. posted the faster year-over-year revenue change (20.1% vs -6.4%). Over the past eight quarters, Bandwidth Inc.'s revenue compounded faster (9.7% CAGR vs 4.2%).
Bandwidth Inc. is a communications platform as a service company. It sells software application programming interfaces for voice, text messaging and emergency services, using its own global IP voice network.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
BAND vs TECH — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $208.8M | $295.9M |
| Net Profit | $4.0M | $38.0M |
| Gross Margin | 37.3% | 64.6% |
| Operating Margin | 60.5% | 18.4% |
| Net Margin | 1.9% | 12.8% |
| Revenue YoY | 20.1% | -6.4% |
| Net Profit YoY | 200.0% | 68.3% |
| EPS (diluted) | $-0.08 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $208.8M | — | ||
| Q4 25 | $207.7M | $295.9M | ||
| Q3 25 | $191.9M | — | ||
| Q2 25 | $180.0M | $317.0M | ||
| Q1 25 | $174.2M | $316.2M | ||
| Q4 24 | $210.0M | $297.0M | ||
| Q3 24 | $193.9M | $289.5M | ||
| Q2 24 | $173.6M | $306.1M |
| Q1 26 | $4.0M | — | ||
| Q4 25 | — | $38.0M | ||
| Q3 25 | $-1.2M | — | ||
| Q2 25 | $-4.9M | $-17.7M | ||
| Q1 25 | $-3.7M | $22.6M | ||
| Q4 24 | — | $34.9M | ||
| Q3 24 | $413.0K | $33.6M | ||
| Q2 24 | $4.1M | $40.6M |
| Q1 26 | 37.3% | — | ||
| Q4 25 | 37.6% | 64.6% | ||
| Q3 25 | 38.5% | — | ||
| Q2 25 | 39.8% | 62.7% | ||
| Q1 25 | 41.0% | 67.9% | ||
| Q4 24 | 36.4% | 65.3% | ||
| Q3 24 | 37.7% | 63.2% | ||
| Q2 24 | 37.3% | 66.4% |
| Q1 26 | 60.5% | — | ||
| Q4 25 | -1.9% | 18.4% | ||
| Q3 25 | -1.0% | — | ||
| Q2 25 | -2.1% | -7.5% | ||
| Q1 25 | -2.7% | 12.2% | ||
| Q4 24 | -1.3% | 16.0% | ||
| Q3 24 | -0.5% | 13.8% | ||
| Q2 24 | -3.5% | 15.0% |
| Q1 26 | 1.9% | — | ||
| Q4 25 | — | 12.8% | ||
| Q3 25 | -0.6% | — | ||
| Q2 25 | -2.7% | -5.6% | ||
| Q1 25 | -2.1% | 7.1% | ||
| Q4 24 | — | 11.7% | ||
| Q3 24 | 0.2% | 11.6% | ||
| Q2 24 | 2.3% | 13.3% |
| Q1 26 | $-0.08 | — | ||
| Q4 25 | $-0.10 | $0.24 | ||
| Q3 25 | $-0.04 | — | ||
| Q2 25 | $-0.16 | $-0.11 | ||
| Q1 25 | $-0.13 | $0.14 | ||
| Q4 24 | $0.27 | $0.22 | ||
| Q3 24 | $0.01 | $0.21 | ||
| Q2 24 | $-0.17 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $47.3M | $172.9M |
| Total DebtLower is stronger | — | $260.0M |
| Stockholders' EquityBook value | $405.7M | $2.0B |
| Total Assets | $984.2M | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $47.3M | — | ||
| Q4 25 | $111.3M | $172.9M | ||
| Q3 25 | $80.4M | — | ||
| Q2 25 | $68.1M | $162.2M | ||
| Q1 25 | $41.7M | $140.7M | ||
| Q4 24 | $83.8M | $177.5M | ||
| Q3 24 | $79.9M | $187.5M | ||
| Q2 24 | $76.4M | $152.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M |
| Q1 26 | $405.7M | — | ||
| Q4 25 | $400.0M | $2.0B | ||
| Q3 25 | $392.7M | — | ||
| Q2 25 | $384.5M | $1.9B | ||
| Q1 25 | $345.4M | $2.0B | ||
| Q4 24 | $312.5M | $2.1B | ||
| Q3 24 | $336.6M | $2.1B | ||
| Q2 24 | $307.4M | $2.1B |
| Q1 26 | $984.2M | — | ||
| Q4 25 | $1.1B | $2.5B | ||
| Q3 25 | $1.0B | — | ||
| Q2 25 | $1.0B | $2.6B | ||
| Q1 25 | $964.4M | $2.6B | ||
| Q4 24 | $989.2M | $2.7B | ||
| Q3 24 | $1.0B | $2.7B | ||
| Q2 24 | $1.0B | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | — |
| Free Cash FlowOCF − Capex | $-1.0M | — |
| FCF MarginFCF / Revenue | -0.5% | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $38.6M | — | ||
| Q3 25 | $22.2M | — | ||
| Q2 25 | $31.7M | $98.2M | ||
| Q1 25 | $-3.1M | $41.1M | ||
| Q4 24 | $36.5M | $84.3M | ||
| Q3 24 | $20.5M | $63.9M | ||
| Q2 24 | $24.4M | $75.5M |
| Q1 26 | $-1.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $93.3M | ||
| Q1 25 | — | $31.0M | ||
| Q4 24 | — | $77.5M | ||
| Q3 24 | — | $54.7M | ||
| Q2 24 | — | $57.5M |
| Q1 26 | -0.5% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 29.4% | ||
| Q1 25 | — | 9.8% | ||
| Q4 24 | — | 26.1% | ||
| Q3 24 | — | 18.9% | ||
| Q2 24 | — | 18.8% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 3.2% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 3.2% | ||
| Q2 24 | — | 5.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.82× | ||
| Q4 24 | — | 2.42× | ||
| Q3 24 | 49.55× | 1.90× | ||
| Q2 24 | 6.03× | 1.86× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BAND
Segment breakdown not available.
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
